Crestline Management, LP Bluebird Bio, Inc. Transaction History

Crestline Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $1.44 Million - $1.9 Million	-16,209 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $1.62 Million - $2.07 Million	16,209 New	16,209 $2.54 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $1.02 Million - $1.65 Million	-12,594 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $157,918 - $250,033	2,735 Added 27.74%	12,594 $1.73 Million
Q2 2017 Aug 14, 2017	BUY	N/A	9,859	9,859 $1.04 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.